Mark Massaro
Stock Analyst at BTIG
(4.09)
# 492
Out of 5,170 analysts
189
Total ratings
44.97%
Success rate
14.36%
Average return
Main Sectors:
Stocks Rated by Mark Massaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DNA Ginkgo Bioworks Holdings | Maintains: Sell | $9 → $5 | $6.91 | -27.64% | 8 | Mar 12, 2026 | |
| XGN Exagen | Maintains: Buy | $10 → $9 | $2.97 | +203.03% | 7 | Mar 10, 2026 | |
| BLLN BillionToOne | Maintains: Buy | $160 → $140 | $74.00 | +89.19% | 3 | Mar 5, 2026 | |
| CAI Caris Life Sciences | Maintains: Buy | $45 → $38 | $18.81 | +102.02% | 1 | Feb 27, 2026 | |
| CDNA CareDx | Maintains: Buy | $25 → $26 | $17.59 | +47.81% | 6 | Feb 26, 2026 | |
| TEM Tempus AI | Maintains: Buy | $105 → $90 | $48.74 | +84.65% | 7 | Feb 25, 2026 | |
| WGS GeneDx Holdings | Maintains: Buy | $200 → $170 | $73.00 | +132.88% | 8 | Feb 24, 2026 | |
| GH Guardant Health | Maintains: Buy | $140 → $145 | $89.08 | +62.78% | 8 | Feb 20, 2026 | |
| PSNL Personalis | Maintains: Buy | $12 → $13 | $7.19 | +80.81% | 5 | Feb 11, 2026 | |
| ADPT Adaptive Biotechnologies | Maintains: Buy | $21 → $22 | $13.50 | +62.96% | 8 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $830 → $800 | $579.85 | +37.97% | 3 | Feb 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $3.26 | +114.72% | 10 | Dec 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $50 | $25.70 | +94.55% | 6 | Dec 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $230 → $260 | $202.73 | +28.25% | 16 | Dec 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $115.99 | +37.94% | 4 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $103.92 | - | 20 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $7 | $4.86 | +44.03% | 3 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $2.5 | $1.28 | +95.31% | 4 | Sep 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.75 | - | 4 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.12 | - | 8 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $21 | $8.18 | +156.72% | 4 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.85 | - | 1 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.76 | - | 1 | Jan 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $350 → $300 | $126.59 | +136.99% | 6 | Sep 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $52 → $50 | $75.33 | -33.63% | 9 | Nov 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $112 | $194.16 | -42.32% | 10 | Jul 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $155 → $165 | $264.09 | -37.52% | 10 | May 2, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $80 | $16.57 | +382.80% | 9 | Sep 10, 2018 |
Ginkgo Bioworks Holdings
Mar 12, 2026
Maintains: Sell
Price Target: $9 → $5
Current: $6.91
Upside: -27.64%
Exagen
Mar 10, 2026
Maintains: Buy
Price Target: $10 → $9
Current: $2.97
Upside: +203.03%
BillionToOne
Mar 5, 2026
Maintains: Buy
Price Target: $160 → $140
Current: $74.00
Upside: +89.19%
Caris Life Sciences
Feb 27, 2026
Maintains: Buy
Price Target: $45 → $38
Current: $18.81
Upside: +102.02%
CareDx
Feb 26, 2026
Maintains: Buy
Price Target: $25 → $26
Current: $17.59
Upside: +47.81%
Tempus AI
Feb 25, 2026
Maintains: Buy
Price Target: $105 → $90
Current: $48.74
Upside: +84.65%
GeneDx Holdings
Feb 24, 2026
Maintains: Buy
Price Target: $200 → $170
Current: $73.00
Upside: +132.88%
Guardant Health
Feb 20, 2026
Maintains: Buy
Price Target: $140 → $145
Current: $89.08
Upside: +62.78%
Personalis
Feb 11, 2026
Maintains: Buy
Price Target: $12 → $13
Current: $7.19
Upside: +80.81%
Adaptive Biotechnologies
Feb 6, 2026
Maintains: Buy
Price Target: $21 → $22
Current: $13.50
Upside: +62.96%
Feb 3, 2026
Maintains: Buy
Price Target: $830 → $800
Current: $579.85
Upside: +37.97%
Dec 23, 2025
Reiterates: Buy
Price Target: $7
Current: $3.26
Upside: +114.72%
Dec 12, 2025
Maintains: Buy
Price Target: $38 → $50
Current: $25.70
Upside: +94.55%
Dec 5, 2025
Maintains: Buy
Price Target: $230 → $260
Current: $202.73
Upside: +28.25%
Dec 3, 2025
Reiterates: Buy
Price Target: $160
Current: $115.99
Upside: +37.94%
Nov 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $103.92
Upside: -
Nov 10, 2025
Maintains: Buy
Price Target: $6 → $7
Current: $4.86
Upside: +44.03%
Sep 10, 2025
Reiterates: Buy
Price Target: $2.5
Current: $1.28
Upside: +95.31%
Aug 11, 2025
Downgrades: Neutral
Price Target: n/a
Current: $0.75
Upside: -
Sep 10, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.12
Upside: -
May 2, 2024
Maintains: Buy
Price Target: $23 → $21
Current: $8.18
Upside: +156.72%
Mar 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.85
Upside: -
Jan 20, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.76
Upside: -
Sep 22, 2020
Maintains: Hold
Price Target: $350 → $300
Current: $126.59
Upside: +136.99%
Nov 11, 2019
Maintains: Hold
Price Target: $52 → $50
Current: $75.33
Upside: -33.63%
Jul 24, 2019
Maintains: Buy
Price Target: $108 → $112
Current: $194.16
Upside: -42.32%
May 2, 2019
Maintains: Hold
Price Target: $155 → $165
Current: $264.09
Upside: -37.52%
Sep 10, 2018
Maintains: Buy
Price Target: $78 → $80
Current: $16.57
Upside: +382.80%